{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:46:16Z","timestamp":1791582376723,"version":"4.3.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Inflammation and oxidative stress are recognized as important contributors to Parkinson\u2019s disease pathogenesis. As such, genetic variability in these pathways could have a role in susceptibility for the disease as well as in the treatment outcome. Dopaminergic treatment is effective in management of motor symptoms, but poses a risk for motor and non-motor adverse events. Our aim was to evaluate the impact of selected single-nucleotide polymorphisms in genes involved in inflammation and oxidative stress on Parkinson\u2019s disease susceptibility and the occurrence of adverse events of dopaminergic treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In total, 224 patients were enrolled, and their demographic and clinical data on the disease course were collected. Furthermore, a control group of 146 healthy Slovenian blood donors were included for Parkinson\u2019s disease\u2019 risk evaluation. Peripheral blood was obtained for DNA isolation. Genotyping was performed for <jats:italic>NLRP3<\/jats:italic> rs35829419, <jats:italic>CARD8<\/jats:italic> rs2043211, <jats:italic>IL1\u03b2<\/jats:italic> rs16944, <jats:italic>IL1\u03b2<\/jats:italic> rs1143623, <jats:italic>IL6<\/jats:italic> rs1800795, <jats:italic>CAT<\/jats:italic> rs1001179, <jats:italic>CAT<\/jats:italic> rs10836235, <jats:italic>SOD2<\/jats:italic> rs4880, <jats:italic>NOS1<\/jats:italic> rs2293054, <jats:italic>NOS1<\/jats:italic> rs2682826, <jats:italic>TNF-\u03b1<\/jats:italic> rs1800629, and <jats:italic>GPX1<\/jats:italic> rs1050450. Logistic regression was used for analysis of possible associations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We observed a nominally significant association of the <jats:italic>IL1\u03b2<\/jats:italic> rs1143623 C allele with the risk for Parkinson\u2019s disease <jats:bold>(<\/jats:bold>OR\u2009=\u20090.59; 95%CI\u2009=\u20090.38\u20130.92, <jats:italic>p<\/jats:italic>\u2009=\u20090.021). <jats:italic>CAT<\/jats:italic> rs1001179 A allele was significantly associated with peripheral edema (OR\u2009=\u20090.32; 95%CI\u2009=\u20090.15\u20130.68; <jats:italic>p<\/jats:italic>\u2009=\u20090.003). Other associations observed were only nominally significant after adjustments: <jats:italic>NOS1<\/jats:italic> rs2682826 A allele and excessive daytime sleepiness and sleep attacks (OR\u2009=\u20091.75; 95%CI\u2009=\u20091.00\u20133.06, <jats:italic>p<\/jats:italic>\u2009=\u20090.048), <jats:italic>SOD2<\/jats:italic> rs4880 T allele and nausea\/vomiting (OR\u2009=\u20090.49, 95%CI\u2009=\u20090.25\u20130.94; <jats:italic>p<\/jats:italic>\u2009=\u20090.031), <jats:italic>IL1\u03b2<\/jats:italic> rs1143623 C allele and orthostatic hypotension (OR\u2009=\u20090.57, 95%CI\u2009=\u20090.32\u20131.00, <jats:italic>p<\/jats:italic>\u2009=\u20090.050), and <jats:italic>NOS1<\/jats:italic> rs2682826 A allele and impulse control disorders (OR\u2009=\u20092.59; 95%CI\u2009=\u20091.09\u20136.19; <jats:italic>p<\/jats:italic>\u2009=\u20090.032). We did not find any associations between selected polymorphisms and motor adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Apart from some nominally significant associations, one significant association between <jats:italic>CAT<\/jats:italic> genetic variability and peripheral edema was observed\u00a0as well. Therefore, the results of our study suggest some links between genetic variability in inflammation- and oxidative stress-related pathways and non-motor adverse events of dopaminergic treatment. However, the investigated polymorphisms do not play a major role in the occurrence of the disease and the adverse events of dopaminergic treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12974-019-1439-y","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T21:02:59Z","timestamp":1551301379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson\u2019s disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Sara","family":"Reden\u0161ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161an","family":"Flisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Kojovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica Gregori\u010d","family":"Kramberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejan","family":"Georgiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvezdan","family":"Pirto\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Tro\u0161t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-6649","authenticated-orcid":false,"given":"Vita","family":"Dol\u017ean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"key":"1439_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017;3:13.","journal-title":"Nat Rev Dis Primers"},{"key":"1439_CR2","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1007\/s00018-013-1352-y","volume":"70","author":"M Deleidi","year":"2013","unstructured":"Deleidi M, Gasser T. The role of inflammation in sporadic and familial Parkinson\u2019s disease. Cell Mol Life Sci. 2013;70:4259\u201373.","journal-title":"Cell Mol Life Sci"},{"key":"1439_CR3","doi-asserted-by":"crossref","unstructured":"Reden\u0161ek S, Tro\u0161t M, Dol\u017ean V. Genetic determinants of Parkinson\u2019s disease: can they help to stratify the patients based on the underlying molecular defect? Front Aging Neurosci. 2017;9:1\u201317.","DOI":"10.3389\/fnagi.2017.00020"},{"key":"1439_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386:896\u2013912.","journal-title":"Lancet"},{"key":"1439_CR5","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.3892\/mmr.2014.2563","volume":"10","author":"J Yan","year":"2014","unstructured":"Yan J, Fu Q, Cheng L, Zhai M, Wu W, Huang L, Du G. Inflammatory response in Parkinson\u2019s disease (review). Mol Med Rep. 2014;10:2223\u201333.","journal-title":"Mol Med Rep"},{"key":"1439_CR6","doi-asserted-by":"publisher","first-page":"70064","DOI":"10.1016\/S1353-8020(11)70064-5","volume":"18","author":"S Phani","year":"2012","unstructured":"Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord. 2012;18:70064\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"1439_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ane.12590","volume":"135","author":"AD Andersen","year":"2017","unstructured":"Andersen AD, Binzer M, Stenager E, Gramsbergen JB. Cerebrospinal fluid biomarkers for Parkinson\u2019s disease - a systematic review. Acta Neurol Scand. 2017;135:34\u201356.","journal-title":"Acta Neurol Scand"},{"key":"1439_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1371\/journal.pone.0055375","volume":"8","author":"G Codolo","year":"2013","unstructured":"Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, de Bernard M. Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS One. 2013;8:31.","journal-title":"PLoS One"},{"key":"1439_CR9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/hmg\/ddt554","volume":"23","author":"P Holmans","year":"2014","unstructured":"Holmans P, Moskvina V, Jones L, Sharma M, Vedernikov A, Buchel F, Saad M, Bras JM, Bettella F, Nicolaou N, et al. A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson\u2019s disease (vol 22, pg 1039, 2013). Hum Mol Genet. 2014;23:562.","journal-title":"Hum Mol Genet"},{"key":"1439_CR10","doi-asserted-by":"publisher","first-page":"016","DOI":"10.1186\/s12974-016-0778-1","volume":"14","author":"C Ghadery","year":"2017","unstructured":"Ghadery C, Koshimori Y, Coakeley S, Harris M, Rusjan P, Kim J, Houle S, Strafella AP. Microglial activation in Parkinson\u2019s disease using [(18)F]-FEPPA. J Neuroinflammation. 2017;14:016\u20130778.","journal-title":"J Neuroinflammation"},{"key":"1439_CR11","first-page":"70814","volume":"15","author":"Y Ouchi","year":"2009","unstructured":"Ouchi Y, Yagi S, Yokokura M, Sakamoto M. Neuroinflammation in the living brain of Parkinson\u2019s disease. Parkinsonism Relat Disord. 2009;15:70814.","journal-title":"Parkinsonism Relat Disord"},{"key":"1439_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","volume":"21","author":"A Gerhard","year":"2006","unstructured":"Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol Dis. 2006;21:404\u201312.","journal-title":"Neurobiol Dis"},{"key":"1439_CR13","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.cyto.2012.07.030","volume":"60","author":"D Koziorowski","year":"2012","unstructured":"Koziorowski D, Tomasiuk R, Szlufik S, Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson\u2019s disease patients. Cytokine. 2012;60:762\u20136.","journal-title":"Cytokine"},{"key":"1439_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/0304-3940(94)90746-3","volume":"165","author":"M Mogi","year":"1994","unstructured":"Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165:208\u201310.","journal-title":"Neurosci Lett"},{"key":"1439_CR15","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1523\/JNEUROSCI.5321-06.2007","volume":"27","author":"MP Mount","year":"2007","unstructured":"Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, Park DS. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci. 2007;27:3328\u201337.","journal-title":"J Neurosci"},{"key":"1439_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0304-3940(95)12192-7","volume":"202","author":"D Blum-Degen","year":"1995","unstructured":"Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett. 1995;202:17\u201320.","journal-title":"Neurosci Lett"},{"key":"1439_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1371\/journal.pone.0047387","volume":"7","author":"D Lindqvist","year":"2012","unstructured":"Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. Non-motor symptoms in patients with Parkinson\u2019s disease - correlations with inflammatory cytokines in serum. PLoS One. 2012;7:17.","journal-title":"PLoS One"},{"key":"1439_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1600-0404.1998.tb01736.x","volume":"98","author":"T Muller","year":"1998","unstructured":"Muller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand. 1998;98:142\u20134.","journal-title":"Acta Neurol Scand"},{"key":"1439_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s12264-017-0183-5","volume":"33","author":"S Lotankar","year":"2017","unstructured":"Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson\u2019s disease: recent advancement. Neurosci Bull. 2017;33:585\u201397.","journal-title":"Neurosci Bull"},{"key":"1439_CR20","doi-asserted-by":"crossref","unstructured":"Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson\u2019s disease. Front Neuroanat. 2015;9:1\u20139.","DOI":"10.3389\/fnana.2015.00091"},{"key":"1439_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12640-013-9435-y","volume":"25","author":"FA Zucca","year":"2014","unstructured":"Zucca FA, Basso E, Cupaioli FA, Ferrari E, Sulzer D, Casella L, Zecca L. Neuromelanin of the human substantia nigra: an update. Neurotox Res. 2014;25:13\u201323.","journal-title":"Neurotox Res"},{"key":"1439_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5607\/en.2013.22.1.11","volume":"22","author":"O Hwang","year":"2013","unstructured":"Hwang O. Role of oxidative stress in Parkinson\u2019s disease. Exp Neurobiol. 2013;22:11\u20137.","journal-title":"Exp Neurobiol"},{"key":"1439_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/jnr.24185","volume":"96","author":"N Joshi","year":"2018","unstructured":"Joshi N, Singh S. Updates on immunity and inflammation in Parkinson disease pathology. J Neurosci Res. 2018;96:379\u201390.","journal-title":"J Neurosci Res"},{"key":"1439_CR24","first-page":"30002","volume":"8","author":"BL Santos-Lobato","year":"2017","unstructured":"Santos-Lobato BL, Borges V, Ferraz HB, Mata IF, Zabetian CP, Tumas V. Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson\u2019s disease. Nitric Oxide. 2017;8:30002.","journal-title":"Nitric Oxide"},{"key":"1439_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1586\/14737175.2016.1135056","volume":"16","author":"MA Algarni","year":"2016","unstructured":"Algarni MA, Stoessl AJ. The role of biomarkers and imaging in Parkinson\u2019s disease. Expert Rev Neurother. 2016;16:187\u2013203.","journal-title":"Expert Rev Neurother"},{"key":"1439_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/WOX.0b013e3182439613","volume":"5","author":"E Birben","year":"2012","unstructured":"Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5:9\u201319.","journal-title":"World Allergy Organ J"},{"key":"1439_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.expneurol.2017.06.017","volume":"298","author":"GF Crotty","year":"2017","unstructured":"Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol. 2017;298:210\u201324.","journal-title":"Exp Neurol"},{"key":"1439_CR28","first-page":"387","volume":"58","author":"H Okazawa","year":"2014","unstructured":"Okazawa H, Ikawa M, Tsujikawa T, Kiyono Y, Yoneda M. Brain imaging for oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Q J Nucl Med Mol Imaging. 2014;58:387\u201397.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"1439_CR29","doi-asserted-by":"publisher","first-page":"017","DOI":"10.1038\/s41531-017-0032-2","volume":"3","author":"S Sarkar","year":"2017","unstructured":"Sarkar S, Malovic E, Harishchandra DS, Ghaisas S, Panicker N, Charli A, Palanisamy BN, Rokad D, Jin H, Anantharam V, et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson\u2019s disease. NPJ Parkinsons Dis. 2017;3:017\u20130032.","journal-title":"NPJ Parkinsons Dis"},{"key":"1439_CR30","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s11064-017-2185-0","volume":"42","author":"Z Mao","year":"2017","unstructured":"Mao Z, Liu C, Ji S, Yang Q, Ye H, Han H, Xue Z. The NLRP3 inflammasome is involved in the pathogenesis of Parkinson\u2019s disease in rats. Neurochem Res. 2017;42:1104\u201315.","journal-title":"Neurochem Res"},{"key":"1439_CR31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/archneur.64.6.836","volume":"64","author":"AD Wahner","year":"2007","unstructured":"Wahner AD, Sinsheimer JS, Bronstein JM, Ritz B. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch Neurol. 2007;64:836\u201340.","journal-title":"Arch Neurol"},{"key":"1439_CR32","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.envres.2016.09.006","volume":"151","author":"PC Lee","year":"2016","unstructured":"Lee PC, Raaschou-Nielsen O, Lill CM, Bertram L, Sinsheimer JS, Hansen J, Ritz B. Gene-environment interactions linking air pollution and inflammation in Parkinson\u2019s disease. Environ Res. 2016;151:713\u201320.","journal-title":"Environ Res"},{"key":"1439_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jns.2017.12.011","volume":"385","author":"C Agliardi","year":"2018","unstructured":"Agliardi C, Guerini FR, Zanzottera M, Riboldazzi G, Zangaglia R, Bono G, Casali C, Di Lorenzo C, Pacchetti C, Nemni R, Clerici M. TNF-alpha -308 G\/A and -238 G\/A promoter polymorphisms and sporadic Parkinson's disease in an Italian cohort. J Neurol Sci. 2018;385:45\u20138.","journal-title":"J Neurol Sci"},{"key":"1439_CR34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3892\/br.2014.296","volume":"2","author":"D Dai","year":"2014","unstructured":"Dai D, Lin P, Wang Y, Zhou X, Tao J, Jiang D, Zhou H, Ru P, Pan G, Li J, et al. Association of NQO1 and TNF polymorphisms with Parkinson\u2019s disease: a meta-analysis of 15 genetic association studies. Biomed Rep. 2014;2:713\u20138.","journal-title":"Biomed Rep"},{"key":"1439_CR35","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/ajmg.b.30435","volume":"5","author":"YR Wu","year":"2007","unstructured":"Wu YR, Feng IH, Lyu RK, Chang KH, Lin YY, Chan H, Hu FJ, Lee-Chen GJ, Chen CM. Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson\u2019s disease. Am J Med Genet B Neuropsychiatr Genet. 2007;5:300\u20134.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"1439_CR36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.neulet.2011.11.032","volume":"506","author":"M San Luciano","year":"2012","unstructured":"San Luciano M, Ozelius L, Lipton RB, Raymond D, Bressman SB, Saunders-Pullman R. Gender differences in the IL6 -174G>C and ESR2 1730G>A polymorphisms and the risk of Parkinson\u2019s disease. Neurosci Lett. 2012;506:312\u20136.","journal-title":"Neurosci Lett"},{"key":"1439_CR37","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10048-008-0137-1","volume":"9","author":"DB Hancock","year":"2008","unstructured":"Hancock DB, Martin ER, Vance JM, Scott WK. Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease. Neurogenetics. 2008;9:249\u201362.","journal-title":"Neurogenetics"},{"key":"1439_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/mas.20221","volume":"29","author":"H Hwang","year":"2010","unstructured":"Hwang H, Zhang J, Chung KA, Leverenz JB, Zabetian CP, Peskind ER, Jankovic J, Su Z, Hancock AM, Pan C, et al. Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev. 2010;29:79\u2013125.","journal-title":"Mass Spectrom Rev"},{"key":"1439_CR39","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/jnr.22045","volume":"87","author":"T Rife","year":"2009","unstructured":"Rife T, Rasoul B, Pullen N, Mitchell D, Grathwol K, Kurth J. The effect of a promoter polymorphism on the transcription of nitric oxide synthase 1 and its relevance to Parkinson\u2019s disease. J Neurosci Res. 2009;87:2319\u201325.","journal-title":"J Neurosci Res"},{"key":"1439_CR40","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1007\/s12035-015-9274-3","volume":"53","author":"SP Gupta","year":"2016","unstructured":"Gupta SP, Kamal R, Mishra SK, Singh MK, Shukla R, Singh MP. Association of polymorphism of neuronal nitric oxide synthase gene with risk to Parkinson\u2019s disease. Mol Neurobiol. 2016;53:3309\u201314.","journal-title":"Mol Neurobiol"},{"key":"1439_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00401-008-0438-3","volume":"117","author":"JH Power","year":"2009","unstructured":"Power JH, Blumbergs PC. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117:63\u201373.","journal-title":"Acta Neuropathol"},{"key":"1439_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/rej.2010.1080","volume":"14","author":"M Gardaneh","year":"2011","unstructured":"Gardaneh M, Gholami M, Maghsoudi N. Synergy between glutathione peroxidase-1 and astrocytic growth factors suppresses free radical generation and protects dopaminergic neurons against 6-hydroxydopamine. Rejuvenation Res. 2011;14:195\u2013204.","journal-title":"Rejuvenation Res"},{"key":"1439_CR43","doi-asserted-by":"crossref","unstructured":"Bai X, Wey MC, Martinez PA, Shi C, Fernandez E, Strong R. Neurochemical and motor changes in mice with combined mutations linked to Parkinson\u2019s disease. Pathobiol Aging Age Relat Dis. 2017;7:1\u20139.","DOI":"10.1080\/20010001.2017.1267855"},{"key":"1439_CR44","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neulet.2016.02.011","volume":"617","author":"CC de Farias","year":"2016","unstructured":"de Farias CC, Maes M, Bonifacio KL, Bortolasci CC, de Souza NA, Brinholi FF, Matsumoto AK, do Nascimento MA, de Melo LB, Nixdorf SL, et al. Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson's disease and its progression: disease and staging biomarkers and new drug targets. Neurosci Lett. 2016;617:66\u201371.","journal-title":"Neurosci Lett"},{"key":"1439_CR45","doi-asserted-by":"crossref","unstructured":"Yu WJ, Li NN, Tan EK, Cheng L, Zhang JH, Mao XY, Chang XL, Zhao DM, Liao Q, Peng R. No association of four candidate genetic variants in MnSOD and SYNIII with Parkinson's disease in two Chinese populations. PLoS One. 2014;9:1\u20133.","DOI":"10.1371\/journal.pone.0088050"},{"key":"1439_CR46","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/mds.1153","volume":"16","author":"FM Farin","year":"2001","unstructured":"Farin FM, Hitosis Y, Hallagan SE, Kushleika J, Woods JS, Janssen PS, Smith-Weller T, Franklin GM, Swanson PD, Checkoway H. Genetic polymorphisms of superoxide dismutase in Parkinson\u2019s disease. Mov Disord. 2001;16:705\u20137.","journal-title":"Mov Disord"},{"key":"1439_CR47","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. Jama. 2014;311:1670\u201383.","journal-title":"Jama"},{"key":"1439_CR48","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1517\/14740338.2016.1130128","volume":"15","author":"R Ceravolo","year":"2016","unstructured":"Ceravolo R, Rossi C, Del Prete E, Bonuccelli U. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. Expert Opin Drug Saf. 2016;15:181\u201398.","journal-title":"Expert Opin Drug Saf"},{"key":"1439_CR49","first-page":"018","volume":"7","author":"H You","year":"2018","unstructured":"You H, Mariani LL, Mangone G, Le Febvre de Nailly D, Charbonnier-Beaupel F, Corvol JC. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease. Cell Tissue Res. 2018;7:018\u20132813.","journal-title":"Cell Tissue Res"},{"key":"1439_CR50","unstructured":"MDS-UPDRS [http:\/\/www.movementdisorders.org\/MDS-Files1\/PDFs\/MDS-UPDRS-Rating-Scales\/NewUPDRS7308final.pdf]."},{"key":"1439_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuroscience.2014.10.028","volume":"302","author":"N Dzamko","year":"2015","unstructured":"Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson's disease. Neuroscience. 2015;302:89\u2013102.","journal-title":"Neuroscience"},{"key":"1439_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.lfs.2015.05.011","volume":"135","author":"F Shi","year":"2015","unstructured":"Shi F, Kouadir M, Yang Y. NALP3 inflammasome activation in protein misfolding diseases. Life Sci. 2015;135:9\u201314.","journal-title":"Life Sci"},{"key":"1439_CR53","first-page":"5","volume":"37","author":"Z Xu","year":"2009","unstructured":"Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 2009;37:5.","journal-title":"Nucleic Acids Res"},{"key":"1439_CR54","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord. 2010;25:2649\u201353.","journal-title":"Mov Disord"},{"key":"1439_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/omi.2017.0181","volume":"22","author":"S Redensek","year":"2018","unstructured":"Redensek S, Dolzan V, Kunej T. From genomics to omics landscapes of Parkinson\u2019s disease: revealing the molecular mechanisms. Omics. 2018;22:1\u201316.","journal-title":"Omics"},{"key":"1439_CR56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/11539720-000000000-00000","volume":"25","author":"B Knie","year":"2011","unstructured":"Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs. 2011;25:203\u201312.","journal-title":"CNS Drugs"},{"key":"1439_CR57","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S1474-4422(09)70225-X","volume":"8","author":"A Antonini","year":"2009","unstructured":"Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson\u2019s disease. Lancet Neurol. 2009;8:929\u201337.","journal-title":"Lancet Neurol"},{"key":"1439_CR58","first-page":"211","volume":"4","author":"W Schrempf","year":"2014","unstructured":"Schrempf W, Brandt MD, Storch A, Reichmann H. Sleep disorders in Parkinson\u2019s disease. J Park Dis. 2014;4:211\u201321.","journal-title":"J Park Dis"},{"key":"1439_CR59","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/WNF.0b013e31821f0d8b","volume":"34","author":"A Gouraud","year":"2011","unstructured":"Gouraud A, Millaret A, Descotes J, Vial T. Piribedil-induced sleep attacks in patients without Parkinson disease: a case series. Clin Neuropharmacol. 2011;34:104\u20137.","journal-title":"Clin Neuropharmacol"},{"key":"1439_CR60","first-page":"11","volume":"485063","author":"A Park","year":"2011","unstructured":"Park A, Stacy M. Dopamine-induced nonmotor symptoms of Parkinson\u2019s disease. Parkinsons Dis. 2011;485063:11.","journal-title":"Parkinsons Dis"},{"key":"1439_CR61","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0006-8993(03)02484-3","volume":"973","author":"L Chen","year":"2003","unstructured":"Chen L, Majde JA, Krueger JM. Spontaneous sleep in mice with targeted disruptions of neuronal or inducible nitric oxide synthase genes. Brain Res. 2003;973:214\u201322.","journal-title":"Brain Res"},{"key":"1439_CR62","doi-asserted-by":"publisher","first-page":"20272","DOI":"10.1073\/pnas.1314762110","volume":"110","author":"SR Morairty","year":"2013","unstructured":"Morairty SR, Dittrich L, Pasumarthi RK, Valladao D, Heiss JE, Gerashchenko D, Kilduff TS. A role for cortical nNOS\/NK1 neurons in coupling homeostatic sleep drive to EEG slow wave activity. Proc Natl Acad Sci U S A. 2013;110:20272\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1439_CR63","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11318330-000000000-00000","volume":"27","author":"LD Wood","year":"2010","unstructured":"Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson\u2019s disease. Drugs Aging. 2010;27:295\u2013310.","journal-title":"Drugs Aging"},{"key":"1439_CR64","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.seizure.2017.01.005","volume":"46","author":"K Esih","year":"2017","unstructured":"Esih K, Goricar K, Dolzan V, Rener-Primec Z. Antioxidant polymorphisms do not influence the risk of epilepsy or its drug resistance after neonatal hypoxic-ischemic brain injury. Seizure. 2017;46:38\u201342.","journal-title":"Seizure"},{"key":"1439_CR65","first-page":"30018","volume":"31","author":"RA Liddle","year":"2018","unstructured":"Liddle RA. Parkinson\u2019s disease from the gut. Brain Res. 2018;31:30018\u20130.","journal-title":"Brain Res"},{"key":"1439_CR66","first-page":"30019","volume":"31","author":"A Chalazonitis","year":"2018","unstructured":"Chalazonitis A, Rao M. Enteric nervous system manifestations of neurodegenerative disease. Brain Res. 2018;31:30019\u20132.","journal-title":"Brain Res"},{"key":"1439_CR67","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2982.2010.01659.x","volume":"23","author":"P Kashyap","year":"2011","unstructured":"Kashyap P, Farrugia G. Oxidative stress: key player in gastrointestinal complications of diabetes. Neurogastroenterol Motil. 2011;23:111\u20134.","journal-title":"Neurogastroenterol Motil"},{"key":"1439_CR68","doi-asserted-by":"publisher","first-page":"017","DOI":"10.1186\/s13041-017-0340-9","volume":"10","author":"L Puspita","year":"2017","unstructured":"Puspita L, Chung SY, Shim JW. Oxidative stress and cellular pathologies in Parkinson\u2019s disease. Mol Brain. 2017;10:017\u20130340.","journal-title":"Mol Brain"},{"key":"1439_CR69","first-page":"24","volume":"15","author":"JG Morris","year":"1978","unstructured":"Morris JG. A review of some aspects of the pharmacology of levodopa. Clin Exp Neurol. 1978;15:24\u201350.","journal-title":"Clin Exp Neurol"},{"key":"1439_CR70","doi-asserted-by":"publisher","first-page":"003","DOI":"10.1016\/j.ncl.2008.05.003","volume":"26","author":"KL Chou","year":"2008","unstructured":"Chou KL. Adverse events from the treatment of Parkinson\u2019s disease. Neurol Clin. 2008;26:003.","journal-title":"Neurol Clin"},{"key":"1439_CR71","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fneur.2013.00064","volume":"4","author":"\u00c1 S\u00e1nchez-Ferro","year":"2013","unstructured":"S\u00e1nchez-Ferro \u00c1, Benito-Le\u00f3n J, G\u00f3mez-Esteban JC. The management of orthostatic hypotension in Parkinson\u2019s disease. Front Neurol. 2013;4:64. https:\/\/doi.org\/10.3389\/fneur.2013.00064.","journal-title":"Front Neurol"},{"key":"1439_CR72","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1007\/s13277-014-1633-6","volume":"35","author":"AG Kutikhin","year":"2014","unstructured":"Kutikhin AG, Yuzhalin AE, Volkov AN, Zhivotovskiy AS, Brusina EB. Correlation between genetic polymorphisms within IL-1B and TLR4 genes and cancer risk in a Russian population: a case-control study. Tumour Biol. 2014;35:4821\u201330.","journal-title":"Tumour Biol"},{"key":"1439_CR73","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/HYPERTENSIONAHA.117.10365","volume":"71","author":"M Johansson","year":"2018","unstructured":"Johansson M, Ricci F, Aung N, Sutton R, Melander O, Fedorowski A. Proteomic profiling for cardiovascular biomarker discovery in orthostatic hypotension. Hypertension. 2018;71:465\u201372.","journal-title":"Hypertension"},{"key":"1439_CR74","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijcard.2017.12.020","volume":"259","author":"M Johansson","year":"2018","unstructured":"Johansson M, Ricci F, Aung N, Sutton R, Melander O, Fedorowski A. Inflammatory biomarker profiling in classical orthostatic hypotension: insights from the SYSTEMA cohort. Int J Cardiol. 2018;259:192\u20137.","journal-title":"Int J Cardiol"},{"key":"1439_CR75","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.gene.2018.05.105","volume":"670","author":"A Eddaikra","year":"2018","unstructured":"Eddaikra A, Amroun H, Raache R, Galleze A, Abdallah-Elhadj N, Azzouz M, Mecabih F, Mechti B, Abbadi MC, Touil-Boukoffa C, Attal N. Clinical variables and ethnicity may influenced by polymorphism of CAT -262C\/T and MnSOD 47C\/T antioxidant enzymes in Algerian type1 diabetes without complications. Gene. 2018;670:182\u201392.","journal-title":"Gene"},{"key":"1439_CR76","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/08039488.2016.1240230","volume":"71","author":"M Topaloglu","year":"2017","unstructured":"Topaloglu M, Tuzun E, Gulec H, Bireller ES, Cakmakoglu B, Kucukali CI. Neuronal nitric oxide synthase polymorphisms in obsessive-compulsive disorder. Nord J Psychiatry. 2017;71:115\u20139.","journal-title":"Nord J Psychiatry"},{"key":"1439_CR77","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1017\/S0954579412000661","volume":"24","author":"T Kurrikoff","year":"2012","unstructured":"Kurrikoff T, Lesch KP, Kiive E, Konstabel K, Herterich S, Veidebaum T, Reif A, Harro J. Association of a functional variant of the nitric oxide synthase 1 gene with personality, anxiety, and depressiveness. Dev Psychopathol. 2012;24:1225\u201335.","journal-title":"Dev Psychopathol"},{"key":"1439_CR78","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/ene.13466","volume":"24","author":"S Perez-Lloret","year":"2017","unstructured":"Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destee A, Meissner WG, Tison F, Rascol O. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. Eur J Neurol. 2017;24:1532\u20138.","journal-title":"Eur J Neurol"},{"key":"1439_CR79","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.27414","volume":"33","author":"SP Sardi","year":"2018","unstructured":"Sardi SP, Cedarbaum JM, Brundin P. Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic. Mov Disord. 2018;33:684\u201396.","journal-title":"Mov Disord"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1439-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-019-1439-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1439-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T05:17:53Z","timestamp":1650431873000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-019-1439-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1186\/s12974-019-1439-y","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]},"assertion":[{"value":"15 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Slovenian Ethics Committee for Research in Medicine (42\/05\/16). All patients signed the informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"50"}}